Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer

SANTA MONICA, Calif. & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a biotechnology company pioneering a new class of fully individualized T cell receptor (TCR) therapies to treat cancer, today announced an exclusive, worldwide license agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), for a...

Click to view original post